Literature DB >> 28892459

Romosozumab - Promising or Practice Changing?

Clifford J Rosen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28892459     DOI： 10.1056/NEJMe1711298

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Cellular senescence in bone.

Authors:  Joshua N Farr; Sundeep Khosla
Journal:  Bone       Date:  2019-01-16       Impact factor: 4.398

Review 2.  Drug discovery of sclerostin inhibitors.

Authors:  Sifan Yu; Dijie Li; Ning Zhang; Shuaijian Ni; Meiheng Sun; Luyao Wang; Huan Xiao; Dingdong Liu; Jin Liu; Yuanyuan Yu; Zongkang Zhang; Samuel Tin Yui Yeung; Shu Zhang; Aiping Lu; Zhenlin Zhang; Baoting Zhang; Ge Zhang
Journal:  Acta Pharm Sin B       Date:  2022-01-21       Impact factor: 14.903

Review 3.  MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

Authors:  Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2017-11-07       Impact factor: 6.664

4.  Bone diseases: Romosozumab - on track or derailed?

Authors:  Sundeep Khosla
Journal:  Nat Rev Endocrinol       Date:  2017-10-13       Impact factor: 43.330

5.  Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.

Authors:  Jonas Bovijn; Kristi Krebs; Chia-Yen Chen; Ruth Boxall; Jenny C Censin; Teresa Ferreira; Sara L Pulit; Craig A Glastonbury; Samantha Laber; Iona Y Millwood; Kuang Lin; Liming Li; Zhengming Chen; Lili Milani; George Davey Smith; Robin G Walters; Reedik Mägi; Benjamin M Neale; Cecilia M Lindgren; Michael V Holmes
Journal:  Sci Transl Med       Date:  2020-06-24       Impact factor: 17.956

6.  Circulating levels of sclerostin are associated with cardiovascular mortality.

Authors:  Cristina Novo-Rodríguez; Beatriz García-Fontana; Juan De Dios Luna-Del Castillo; Francisco Andújar-Vera; Verónica Ávila-Rubio; Cristina García-Fontana; Sonia Morales-Santana; Pedro Rozas-Moreno; Manuel Muñoz-Torres
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

7.  Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes.

Authors:  Maria Carolina Medeiros; Natalia Rocha; Elba Bandeira; Isabel Dantas; Conceição Chaves; Mario Oliveira; Francisco Bandeira
Journal:  Int J Nephrol       Date:  2020-02-10

8.  Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Wuyang He; Chunqiu Li; Qingwei Chen; Tingting Xiang; Peng Wang; Jun Pang
Journal:  Aging Clin Exp Res       Date:  2019-11-01       Impact factor: 3.636
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.